Comparative Pharmacology
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus MEFENAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN versus MEFENAMIC ACID.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs MEFENAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
None Documented
None Documented
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Clinical Note
moderateMefenamic acid + Gatifloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMefenamic acid + Rosoxacin
"Mefenamic acid may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMefenamic acid + Levofloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMefenamic acid + Trovafloxacin
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and pH-dependent: alkaline urine increases clearance.
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Category D/X
Category D/X
NSAID / Antiplatelet
NSAID
"Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin."